Treatment of Idiopathic Castleman Disease

Citations of this article
Mendeley users who have this article in their library.


Important progress has been made in the treatment of idiopathic multicentric Castleman disease (iMCD) with the introduction of interleukin-6 targeting monoclonal antibodies. This article describes the clinical results obtained with different treatment modalities and uses this evidence to provide treatment guidelines for the practicing clinician. Much is still to be learned about the pathophysiology of iMCD and further research is urgently needed to develop novel and curative treatment approaches for all patients.




van Rhee, F., Greenway, A., & Stone, K. (2018, February 1). Treatment of Idiopathic Castleman Disease. Hematology/Oncology Clinics of North America. W.B. Saunders.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free